BRIP1 and cancer: Also the third cancer-associated variant studied here, FANCJ M299I, associated with early-onset breast cancer [1], was able to complement FANCJ knock-out cell lines in all experiments to a similar extent as the wild-type construct, despite an altered–in this case increased–unwinding activity.